NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D. will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 11:05 a.m. Eastern Time.
New drug cocktail may show promise in NSCLC patients
A drug approved by the Food and Drug Administration for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from th…
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia
International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.
Uncategorized
Halometer app may quantify patient-reported halos
A halometer application operated on an iPad reliably and objectively quantified the size of patient-reported halos, according to a study.The prospective study included 20 subjects who had a mean age of 27.7 years.
Uncategorized
“FAID 2016” symposium will include panel presentations on Transforming Clinical Research: New End-Points and Regulatory Renewal as part of its February 9-10, 2016, program
BOSTON & PARIS–(BUSINESS WIRE)–“FAID 2016” symposium will include panel presentations on
Transforming Clinical Research: New End-Points and Regulatory Renewal
as part of its February 9-10, 2016, program
Uncategorized
VIDEO: FDA working with glaucoma community, patients in MIGS development
SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum here, Kuldev Singh, MD, MPH, discusses a panel he co-moderated with Eugene de Juan Jr., MD, that featured Wiley Chambers, MD, supervisory medical officer of transplant and ophthalmology products at the FDA, and Malvina Eydelman, MD, division director of ophthalmic device evaluation at the FDA.